Defziff 6 Tablet

Deflazacort (6mg) Tablet

Deflazacort is a corticosteroid used for its antiinflammatory and immunosuppressive properties. It is commonly prescribed for conditions that require the reduction of inflammation and immune system suppression.

Composition (per tablet):

 Deflazacort (6mg): A synthetic corticosteroid with anti-inflammatory and immunosuppressive effects.

Indications:

Deflazacort is used for various conditions, including but not limited to:

- 1. Autoimmune Diseases:
 - Rheumatoid arthritis, lupus erythematosus, and other conditions involving excessive immune system activity.
- 2. Inflammatory Conditions:
 - Inflammatory bowel diseases like Crohn's disease and ulcerative colitis.
 - Chronic obstructive pulmonary disease (COPD) exacerbations.
- 3. Allergic Reactions:
 - Severe allergic conditions, such as asthma, allergic rhinitis, or skin allergies.
- **4.** Management of Certain Cancer-related Symptoms:
 - For reducing inflammation in cases of certain cancers.

Dosage & Administration:

- For Adults:
 - Initial Dose: Typically, 6mg to 12mg per day, depending on the severity of the condition.
 - Maintenance Dose: Often reduced to 4mg to 6mg per day, depending on the patient's response and medical condition.
- For Children:
 - Dosage in pediatric cases is based on weight and the type of disease being treated. It is typically 0.15mg/kg to 0.3mg/kg per day.

Side Effects:

- Common:
 - Weight gain, fluid retention, and swelling (edema).
 - o Increased appetite.
 - Stomach irritation, nausea, or indigestion.
 - o Insomnia or mood changes.
- Serious (rare but severe):
 - Increased blood pressure (hypertension), diabetes, or high blood sugar levels.

If any of these serious side effects occur, contact a healthcare professional immediately.

Precautions:

- 1. Infections:
 - Deflazacort can suppress the immune system, making it harder for the body to fight infections.
- 2. Diabetes:

 Deflazacort can increase blood sugar levels. Diabetic patients should be monitored closely for any increase in blood glucose levels.

3. Osteoporosis:

 Prolonged use of corticosteroids like Deflazacort can lead to bone thinning (osteoporosis).

4. Gastrointestinal Issues:

 It can increase the risk of ulcers and gastrointestinal bleeding, particularly when used in high doses or for prolonged periods.

5. Pregnancy and Breastfeeding:

 Pregnancy: Deflazacort is classified as a Category C drug during pregnancy, meaning it may have harmful effects on the fetus.

6. Psychiatric Effects:

 Long-term use can sometimes lead to psychiatric effects such as mood swings, depression, or even psychosis.

Drug Interactions:

- Non-steroidal anti-inflammatory drugs (NSAIDs):
 - Concurrent use with NSAIDs can increase the risk of gastrointestinal irritation, bleeding, and ulcers.

Anticoagulants:

 Deflazacort may affect the effectiveness of anticoagulants (blood thinners) like warfarin, increasing the risk of bleeding.

Vaccines:

- Live vaccines may be less effective, and there may be a risk of developing the infection they are meant to prevent.
- Diuretics and Antihypertensives:
 - Deflazacort can alter the effectiveness of blood pressure medications and diuretics,

especially in cases of fluid retention and electrolyte imbalance.

Always inform your doctor about any other medications or supplements you are taking.

Storage:

- Store at room temperature (15-30°C) in a cool, dry place.
- Keep the medication in its original container, tightly closed, and out of reach of children.

Note:

- Tapering: Do not abruptly stop taking Deflazacort without medical supervision, as sudden cessation can cause withdrawal symptoms or adrenal insufficiency.
- Adherence to Treatment: Ensure adherence to the prescribed dose and follow-up with your healthcare provider to monitor the effectiveness and adjust dosage if necessary.
- This medication should only be used under the supervision of a healthcare provider, particularly for long-term therapy, to ensure safety and efficacy.

Manufactured in India for:



Calon Lifecare Pvt. Ltu.

(An ISO 9001: 2015 Certified Co.) Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for